{"title":"EGFR突变阳性NSCLC从第一代或第二代EGFR- tki切换到奥西替尼。","authors":"Fumio Imamura, Takako Inoue, Kei Kunimasa, Aki Kubota, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Madoka Kimura, Kika Kuno, Hayato Kawachi, Toru Kumagai","doi":"10.2217/lmt-2020-0005","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for <i>EGFR</i> mutation-positive NSCLC.</p><p><strong>Materials & methods: </strong>Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for <i>T790M</i>-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.</p><p><strong>Results: </strong>Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.</p><p><strong>Conclusion: </strong>Switch use of osimertinib seemed to produce improved efficacy for patients with activating <i>EGFR</i> mutations, because of the lack of patient selection via <i>T790M</i>.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"9 2","pages":"LMT29"},"PeriodicalIF":0.9000,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0005","citationCount":"4","resultStr":"{\"title\":\"Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLC.\",\"authors\":\"Fumio Imamura, Takako Inoue, Kei Kunimasa, Aki Kubota, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Madoka Kimura, Kika Kuno, Hayato Kawachi, Toru Kumagai\",\"doi\":\"10.2217/lmt-2020-0005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for <i>EGFR</i> mutation-positive NSCLC.</p><p><strong>Materials & methods: </strong>Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for <i>T790M</i>-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.</p><p><strong>Results: </strong>Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.</p><p><strong>Conclusion: </strong>Switch use of osimertinib seemed to produce improved efficacy for patients with activating <i>EGFR</i> mutations, because of the lack of patient selection via <i>T790M</i>.</p>\",\"PeriodicalId\":43551,\"journal\":{\"name\":\"Lung Cancer Management\",\"volume\":\"9 2\",\"pages\":\"LMT29\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2020-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/lmt-2020-0005\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2020-0005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC.
Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC.
Materials & methods: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.
Results: Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.
Conclusion: Switch use of osimertinib seemed to produce improved efficacy for patients with activating EGFR mutations, because of the lack of patient selection via T790M.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
